Search

everythinglearnresearchcommunity

for

Search:↓

The user was prescribed 0.3% topical finasteride with 5% minoxidil for use on the temples twice daily, while continuing minoxidil on the full scalp. Replies suggested using the treatment once daily and questioned the logic of treating only the temples, with one suggesting dilution for use across the entire scalp.

The user is using a hair loss treatment regimen that includes double the recommended dose of Minoxidil foam once nightly, a mix of RU58841 and stemoxydine after the Minoxidil dries, ketoconazole every other day, and weekly microneedling with alternating depths. They are also considering starting finasteride soon.

A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

A 51-year-old on TRT plans to use steroids and is concerned about hair loss, considering topical treatments like Hair Rescue with RU58841 and finasteride, along with Nioxin shampoo. They are cautious about using oral DHT blockers due to potential interactions with steroids like Tren and Anavar.

A 27-year-old male is using minoxidil 5% nightly and alternating between three hair serums during the day, seeking advice on whether this routine is beneficial or overly complicated. Responses suggest simplifying the routine by focusing on minoxidil, possibly increasing its concentration, and considering finasteride or dutasteride instead of multiple serums.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

A user beginning a treatment of pyrilutamide for hair loss, which they plan on updating progress on every month.

A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.

After 8 months of using topical finasteride, hair miniaturization continues, raising concerns about its effectiveness. Microneedling is suggested as a possible complementary treatment.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

The conversation discusses the importance of scalp biopsies for diagnosing hair loss conditions like DUPA and Retrograde, which may not be just AGA. It emphasizes that treatments like finasteride and dutasteride may not work if the condition is autoimmune.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

The user experienced significant hair thinning in two months and is questioning if this is typical of male pattern baldness. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

The conversation discusses treating male pattern baldness with topical products containing Saw Palmetto extract. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user shared progress pictures showing improvement from NW6 diffuse to NW1 after 5 months of finasteride and 2 months of dutasteride. Another user asked if these treatments affected beard or body hair thickness.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The user had a hair transplant in March 2025 and has been using finasteride since 2023, which halted hair loss but didn't fully restore density. They plan to use dutasteride twice weekly, finasteride five times a week, and saw palmetto to improve hair thickness.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

The user has been experiencing hair loss since having COVID and has low vitamin D levels; they are seeing some improvement in their crown and hairline after starting vitamin D supplements. Commenters suggest the hair loss pattern is consistent with male pattern baldness (MPD) and varies by individual.

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.